beta 2 Adrenergic Receptor anticorps

N° du produit ABIN2192080

Détail du produit anti-beta 2 Adrenergic Receptor anticorps

Antigène: beta 2 Adrenergic Receptor (ADRB2) (Adrenergic, beta-2-, Receptor, Surface (ADRB2))

Reactivité: Humain

Hôte: Souris

Clonalité: Monoclonal

Conjugué: Cet anticorp beta 2 Adrenergic Receptor est non-conjugé

Application: Flow Cytometry (FACS), Functional Studies (Func), Immunoassay (IA)

Réactivité croisée (Details): Cross reactivity: Rat : Yes, Guinea Pig : Yes

Stérilité: 0.2 μm filtered

Clone: 6H8

Isotype: IgG1

Information d'application

Indications d'application: For flow cytometry, dilutions to be used depend on detection system applied. It is recommended that users test the reagent and determine their own optimal dilutions. The typical starting working dilution is 1:50. For functional studies, in vitro dilutions have to be optimized in user's experimental setting. Positive Human epidermoid carcinoma cell A431 line control

Restrictions: For Research Use only

Stockage

Buffer: PBS, containing 0.1 % bovine serum albumin

Stock: 4 °C

Stockage commentaire: Product should be stored at 4 °C. Under recommended storage conditions, product is stable for at least one year. The exact expiry date is indicated on the label.

Références pour anticorps anti-beta 2 Adrenergic Receptor (ABIN2192080)

Mijares, Lebesgue, Wallukat, Hoebeke: "From agonist to antagonist: Fab fragments of an agonist-like monoclonal anti-beta(2)-adrenoceptor antibody behave as antagonists." dans: Molecular pharmacology, Vol. 58, Issue 2, pp. 373-9, (2000) (PubMed).

Lebesgue, Wallukat, Mijares, Granier, Argibay, Hoebeke: "An agonist-like monoclonal antibody against the human beta2-adrenoceptor." dans: European journal of pharmacology, Vol. 348, Issue 1, pp. 123-33, (1998) (PubMed).

Détails sur beta 2 Adrenergic Receptor

Antigène: beta 2 Adrenergic Receptor (ADRB2) (Adrenergic, beta-2-, Receptor, Surface (ADRB2))

Autre désignation: Beta2-Adrenoceptor (ADRB2 Produits)

Sujet: The monoclonal antibody 6H8 recognizes human beta2-adrenoceptor. The b -adrenoceptors can be divided into b1, b2, b3 and b4-adrenoceptors defined in terms of agonist potencies, b2-adrenoceptors displayed a higher selectivity for nor-adrenaline than for adrenaline. B2-receptors are mainly postsynaptic and are located on a number of tissues including blood vessels, bronchi, GIT, skeletal muscle, liver and mast cell. Activation results in vasodilatation, bronchodilation, relaxation of the GIT, glycogenolysis in the liver, tremor in skeletal muscle and inhibition of histamine release from mast cells. Transduction is via G-proteins coupled to the intracellular second messenger adenylate cyclase. B- receptors are positively coupled to adenylate cyclase via activation of Gs G-protein, however activation of the b2-adrenoceptors results in stimulation and inhibition of adenylate cyclase. The b2- receptor selective agonists are widely used in the treatment of asthma and other related bronchospastic conditions. They are commonly used in the treatment of angina pectoris, cardiac arrhythmia and for the long-term treatment of patients who survive myocardial infarction. B-receptor antagonists have also been used as anti-hypertensive for a number of years. Beta -blockers have also proven useful in the treatment of conditions such as migraine, anxiety disorders, hyperthyroidism, alcohol withdrawal and when applied topically are useful in the treatment of glaucoma and ocular hypertension. Immunogen Free peptide Beta2-H19C

Pathways: cAMP Metabolic Process, Synaptic Membrane, Regulation of G-Protein Coupled Receptor Protein Signaling, Brown Fat Cell Differentiation